Exposure categories and regimens | Products included in regimen |
LAMA and LABA dual therapy | |
LAMA+LABA/ICS | Concurrent use of LAMA single-agent product and LABA/ICS combination product |
LAMA+LABA+ICS | Concurrent use of three single-agent products (LAMA, LABA and ICS) |
LAMA+LABA | Concurrent use of LAMA and LABA single-agent products |
LAMA therapy | |
LAMA | Use of LAMA single-agent product only |
LAMA+ICS | Concurrent use of LAMA and ICS single-agent products |
LABA therapy | |
LABA | Use of LABA single-agent product only |
LABA+ICS | Concurrent use of LABA and ICS single-agent products |
LABA/ICS | Use of LABA/ICS combination product only |
ICS monotherapy* | |
ICS | Use of ICS single-agent product only |
*By design, all cohort members had used a long-acting bronchodilator before the episode of ICS monotherapy.
ICS, Inhaled corticosteroid; LABA, long-acting beta2 agonist; LAMA, long-acting muscarinic antagonist.